Advanced, multi-target assay design
with RNase P human sample confirmation

Thermo Fisher Scientific continues to provide the gold standard of testing with our evolved, PCR-based TaqPath RNase P Combo Kit 2.0 test, which was established to help laboratories quickly diagnose COVID-19 caused by SARS-CoV- 2 infection.

TaqPath RNase P Combo Kit 2.0 was developed with an advanced, multi-target assay design and RNase P control for human sample confirmation.

TaqPath COVID-19 RNase P Combo Kit 2.0—Now available!

Features:

  • Recommended for use with RNA extracted from nasopharyngeal and anterior nasal swabs
  • Detects active infections from individuals suspected of COVID-19 by their healthcare provider, as well as asymptomatic individuals
  • Utilizes human sample confirmation RNase P gene as an internal control
  • Go from sample to result in ~3 hours

Fill out the form, and a sales representative will be in touch.

For Emergency Use Authorization. For in vitro diagnostics. For Prescription use only. Regulatory requirements vary by country. Product may not be available in your geographic region. © 2021 Thermo Fisher Scientific, Inc.

All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

*
*
*
*
*
*
*

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.